Company intelligence / Profile preview

Achilles Therapeutics plc

London, United Kingdom

Ownership: Public · ACHL
Employees: ~215
Development stage: Phase 1

Overview

The company discontinued its TIL-based cNeT program and closed Phase I/IIa CHIRON and THETIS clinical trials in September 2024 as they did not meet goals for commercial viability. The company entered liquidation in March 2025.

Therapeutic areas: Oncology
Modalities: T cell therapiesTIL-based therapies
Industry: Biotech

Drug pipeline

2 assets

ATL001

1 more asset in the full pipeline.

Request access →

Partnerships

Arcturus Therapeutics (research pact established in May 2024)

Financials

Market cap: $60.8M
Total revenue: $0
Enterprise value: $-21.6M

Beyond the preview

Go deeper on Achilles Therapeutics plc.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Achilles Therapeutics plc.

Explore the full profile